The Real Cost of a Failed Serialization Audit: What 3 Recent FDA/EMA Warning Letters Reveal

Sun Teknovation Pvt Ltd is a Leading Provider of Machine Vision and Track & Trace Serialization Solutions for the Global Pharmaceutical Industry.

Most pharma manufacturers are aware that serialization is mandatory. What many underestimate is what actually happens when an audit goes wrong. It is not just a warning letter sitting in a regulatory file. It is halted production, shipments held at borders, product recalls under scrutiny, and in some cases, consent decrees that restructure an entire manufacturing operation.

Three recent enforcement actions by the FDA and EMA have put FDA Warning Letters Serialization failures back in the spotlight. The details are specific, the consequences are measurable, and the patterns are repeatable — meaning other manufacturers are at risk of walking into the same traps.

Why Serialization Audits Are Getting Stricter

Regulatory bodies have progressively tightened their expectations around FDA EMA Serialization Requirements over the past several years. The shift from guidance documents to enforceable mandates is now complete in most major markets. The FDA's DSCSA enforcement framework, the EU Falsified Medicines Directive (EU FMD), and other regional regulations now hold manufacturers to a high standard of technical documentation, system validation, and data integrity.

Auditors are no longer satisfied with proof that a serialization system exists. They want evidence that it works — consistently, at line speed, with complete and accurate data that can be verified end-to-end across the supply chain.When that evidence is incomplete or inconsistent, the result is a Serialization Audit Failure — and that is where the real cost begins.

What 3 Recent FDA/EMA Warning Letters Revealed

While specific company names in warning letters are public record, the patterns across recent enforcement actions point to three consistent failure areas:

1. Incomplete or Unverifiable Aggregation Data

One of the most frequently cited issues in recent FDA Warning Letters Serialization cases involves aggregation — the process of linking serial numbers at the unit level to carton, case, and pallet levels. Inspectors found that manufacturers had serialization systems in place at the item level but lacked validated, verifiable aggregation records that connected those individual units to their shipping containers.

The consequence: an entire shipment's traceability data became unreliable. Regulators could not verify the chain of custody, which triggered an import alert and a halt on distribution.

What this means for you: Aggregation is not optional. The current FDA EMA Serialization Requirements are not met by a serialization solution that manages unit-level coding without overseeing the entire packaging hierarchy.

2. System Validation Gaps and Data Integrity Failures

A second pattern seen across recent enforcement actions involves system validation. Manufacturers had track and trace systems deployed, but the validation documentation was either outdated, incomplete, or did not reflect the actual software version in production.

In one case, a software update had been applied to the serialization platform without a corresponding validation protocol update — a direct Drug Serialization Non-Compliance finding under 21 CFR Part 11 data integrity expectations.

What this implies for you: A documented validation evaluation is necessary for each hardware or software change to your serialization system. Regulators treat an unvalidated change as equivalent to operating an unvalidated system.

3. Missing Exception Handling and Re-Work Documentation

The third pattern is perhaps the most avoidable. During line operations, exceptions happen — labels fail to apply correctly, codes scan as unreadable, products are re-worked. Regulators found that manufacturers lacked documented procedures and electronic records for how these exceptions were handled.

When an inspector asks what happened to a product unit that triggered a serialization error during packaging, and there is no documented answer — that is a Serialization Audit Failure that cascades across your entire quality system.

What this means for you: Exception handling must be built into your serialization workflow, not managed manually on paper. Every re-work event needs an electronic record linked back to the original serial number.

The Real Cost: Beyond the Warning Letter

A warning letter is the visible part of the consequence. The actual cost of Drug Serialization Non-Compliance spreads much further:

• Import Alerts — products blocked at the US border, with no distribution until the situation is resolved
• Mandatory Recalls — triggered when traceability data cannot verify product authenticity across the chain
• Consent Decrees — court-ordered operational restrictions that can last years and require third-party oversight
• Lost Market Access — export markets with strict FDA EMA Serialization Requirements may delist non-compliant suppliers.
• Internal Remediation Costs — system upgrades, revalidation, additional staffing, and regulatory consulting fees
• Reputational Impact — clients, distributors, and procurement bodies monitor FDA and EMA enforcement databases.

The compounding effect of these consequences means that a single Serialization Audit Failure can cost a manufacturer several times more than a fully compliant serialization infrastructure would have cost to build correctly from the start.

What Regulators Actually Want to See

Based on the patterns in recent enforcement actions and the current state of FDA EMA Serialization Requirements, here is what a robust Pharmaceutical Serialization Compliance program needs to demonstrate during an audit:

• End-to-end traceability — every serialized unit linked to its aggregated hierarchy, with records that can be queried and verified in real time.
• Validated systems — current validation documentation that reflects the actual deployed software and hardware configuration.
• Electronic exception records — documented workflows for every line exception, re-work event, and destroyed unit.
• Integration with regulatory reporting — real-time or near-real-time data submission to applicable regulatory repositories (DSCSA, EU FMD hub, etc.)
• Audit trail integrity — tamper-evident electronic records meeting 21 CFR Part 11 and Annex 11 data integrity standards.

These are not aspirational standards. They are the baseline that current inspectors apply in the field.

Building a Compliance-Ready Serialization Program

The manufacturers who pass audits without findings share one common characteristic — they treat Pharmaceutical Serialization Compliance as a live operational discipline, not a project that was completed at some point in the past.

That means:

• Regular internal audits of serialization data quality, not just system availability
• Periodic revalidation reviews when systems are updated.
• Clear SOPs for exception handling that are actually practiced on the line
• Technology infrastructure that captures data automatically rather than relying on manual entry or paper records

The difference between a facility that receives a warning letter and one that does not often come down to whether the serialization system is truly integrated into production operations — or merely installed alongside them.

Why Choose Us

At Sun Teknovation Pvt Ltd., we have spent over 14 years building serialization and machine vision solutions specifically for the demands of regulated pharmaceutical manufacturing. Our track and trace platform — eTrack — is designed to address the exact compliance gaps that regulators are identifying in current enforcement actions. From complete aggregation management to validated electronic exception records and real-time regulatory reporting integration, our systems are built to perform under audit conditions, not just under production conditions.With more than 1,250 installations completed and clients across 60+ countries, Sun Teknovation Pvt Ltd brings practical, field-proven expertise to every deployment. We do not just supply equipment — we work with your team to build a Pharmaceutical Serialization Compliance program that holds up when it matters most. When regulators walk in, our clients are ready.

Conclusion

A failed serialization audit is not a paperwork problem — it is an operational and commercial crisis that can take years to fully recover from. The patterns in recent FDA Warning Letters Serialization enforcement actions are clear: aggregation gaps, system validation failures, and missing exception records are the vulnerabilities regulators are targeting right now. Drug Serialization Non-Compliance carries consequences that extend far beyond the warning letter itself. The manufacturers who protect their market access, export approvals, and client relationships are those who invest in validated, integrated, technology-backed serialization infrastructure — and treat compliance as an ongoing operational standard, not a one-time checkbox. Sun Teknovation Pvt Ltd is here to help you get there.

Ready to find out if your serialization system is truly audit-ready? Connect with Sun Teknovation Pvt Ltd today for expert guidance and compliance-ready track and trace solutions. Call us at +91 98982 45695 or email connect@sunteknovation.com to speak with our team and take the next step toward full serialization compliance with confidence.

Frequently Asked Questions